Regulation of protein secretion through controlled aggregation in the endoplasmic reticulum

Science

Volumn 287, Issue 5454, 2000, Pages 826-830

  Rivera, Victor M ^a   Wang, Xiurong ^a   Wardwell, Scott ^a   Courage, Nancy L ^a   Volchuk, Allen ^b   Keenan, Terence ^a   Holt, Dennis A ^a   Gilman, Michael ^a   Orci, Lelio ^c   Cerasoli Jr , Frank ^a   Rothman, James E ^b   Clackson, Tim ^a  

^a ARIAD PHARMACEUTICALS INC   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ARTICLE; ENDOPLASMIC RETICULUM; GENE THERAPY; GLUCOSE BLOOD LEVEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN SECRETION; PROTEIN TRANSPORT;

ANIMALS; BLOOD GLUCOSE; CELL LINE; DIABETES MELLITUS, EXPERIMENTAL; DRUG DELIVERY SYSTEMS; ENDOPLASMIC RETICULUM; FURIN; GENE THERAPY; GOLGI APPARATUS; HUMAN GROWTH HORMONE; HUMANS; IMMUNOPHILINS; INSULIN; KINETICS; LIGANDS; MICE; PROINSULIN; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; SUBTILISINS; TACROLIMUS BINDING PROTEINS; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0034603114     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.287.5454.826     Document Type: Article

References (40)

1. P. D. Kessler et al., Proc. Natl. Acad. Sci. U.S.A. 93, 14082 (1996); S. K. Tripathy et al., Proc. Natl. Acad. Sci. U.S.A. 93, 10876 (1996); R. W. Herzog et al., Proc. Natl. Acad. Sci. U.S.A. 94, 5804 (1997); J. E. Murphy et al., Proc. Natl. Acad. Sci. U.S.A. 94, 13921 (1997); R. O. Snyder et al., Hum. Gene Ther. 8, 1891 (1997); S. Song et al., Proc. Natl. Acad. Sci. U.S.A. 95, 14384 (1998).
2. P. D. Kessler et al., Proc. Natl. Acad. Sci. U.S.A. 93, 14082 (1996); S. K. Tripathy et al., Proc. Natl. Acad. Sci. U.S.A. 93, 10876 (1996); R. W. Herzog et al., Proc. Natl. Acad. Sci. U.S.A. 94, 5804 (1997); J. E. Murphy et al., Proc. Natl. Acad. Sci. U.S.A. 94, 13921 (1997); R. O. Snyder et al., Hum. Gene Ther. 8, 1891 (1997); S. Song et al., Proc. Natl. Acad. Sci. U.S.A. 95, 14384 (1998).
3. P. D. Kessler et al., Proc. Natl. Acad. Sci. U.S.A. 93, 14082 (1996); S. K. Tripathy et al., Proc. Natl. Acad. Sci. U.S.A. 93, 10876 (1996); R. W. Herzog et al., Proc. Natl. Acad. Sci. U.S.A. 94, 5804 (1997); J. E. Murphy et al., Proc. Natl. Acad. Sci. U.S.A. 94, 13921 (1997); R. O. Snyder et al., Hum. Gene Ther. 8, 1891 (1997); S. Song et al., Proc. Natl. Acad. Sci. U.S.A. 95, 14384 (1998).
4. P. D. Kessler et al., Proc. Natl. Acad. Sci. U.S.A. 93, 14082 (1996); S. K. Tripathy et al., Proc. Natl. Acad. Sci. U.S.A. 93, 10876 (1996); R. W. Herzog et al., Proc. Natl. Acad. Sci. U.S.A. 94, 5804 (1997); J. E. Murphy et al., Proc. Natl. Acad. Sci. U.S.A. 94, 13921 (1997); R. O. Snyder et al., Hum. Gene Ther. 8, 1891 (1997); S. Song et al., Proc. Natl. Acad. Sci. U.S.A. 95, 14384 (1998).
5. P. D. Kessler et al., Proc. Natl. Acad. Sci. U.S.A. 93, 14082 (1996); S. K. Tripathy et al., Proc. Natl. Acad. Sci. U.S.A. 93, 10876 (1996); R. W. Herzog et al., Proc. Natl. Acad. Sci. U.S.A. 94, 5804 (1997); J. E. Murphy et al., Proc. Natl. Acad. Sci. U.S.A. 94, 13921 (1997); R. O. Snyder et al., Hum. Gene Ther. 8, 1891 (1997); S. Song et al., Proc. Natl. Acad. Sci. U.S.A. 95, 14384 (1998).
6. P. D. Kessler et al., Proc. Natl. Acad. Sci. U.S.A. 93, 14082 (1996); S. K. Tripathy et al., Proc. Natl. Acad. Sci. U.S.A. 93, 10876 (1996); R. W. Herzog et al., Proc. Natl. Acad. Sci. U.S.A. 94, 5804 (1997); J. E. Murphy et al., Proc. Natl. Acad. Sci. U.S.A. 94, 13921 (1997); R. O. Snyder et al., Hum. Gene Ther. 8, 1891 (1997); S. Song et al., Proc. Natl. Acad. Sci. U.S.A. 95, 14384 (1998).
7. M. Gossen and H. Bujard, Proc. Natl. Acad. Sci. U.S.A 89, 5547 (1992); Y. Wang, B. W. O'Malley Jr., S. Y. Tsai, B. W. O'Malley, Proc. Natl. Acad. Sci. U.S.A. 91, 8180 (1994); D. No, T. P. Yao, R. M. Evans, Proc. Natl. Acad. Sci. U.S.A. 93, 3346 (1996); V. M. Rivera et al., Nature Med. 2, 1028 (1996).
8. M. Gossen and H. Bujard, Proc. Natl. Acad. Sci. U.S.A 89, 5547 (1992); Y. Wang, B. W. O'Malley Jr., S. Y. Tsai, B. W. O'Malley, Proc. Natl. Acad. Sci. U.S.A. 91, 8180 (1994); D. No, T. P. Yao, R. M. Evans, Proc. Natl. Acad. Sci. U.S.A. 93, 3346 (1996); V. M. Rivera et al., Nature Med. 2, 1028 (1996).
9. M. Gossen and H. Bujard, Proc. Natl. Acad. Sci. U.S.A 89, 5547 (1992); Y. Wang, B. W. O'Malley Jr., S. Y. Tsai, B. W. O'Malley, Proc. Natl. Acad. Sci. U.S.A. 91, 8180 (1994); D. No, T. P. Yao, R. M. Evans, Proc. Natl. Acad. Sci. U.S.A. 93, 3346 (1996); V. M. Rivera et al., Nature Med. 2, 1028 (1996).
10. M. Gossen and H. Bujard, Proc. Natl. Acad. Sci. U.S.A 89, 5547 (1992); Y. Wang, B. W. O'Malley Jr., S. Y. Tsai, B. W. O'Malley, Proc. Natl. Acad. Sci. U.S.A. 91, 8180 (1994); D. No, T. P. Yao, R. M. Evans, Proc. Natl. Acad. Sci. U.S.A. 93, 3346 (1996); V. M. Rivera et al., Nature Med. 2, 1028 (1996).
11. D. Bohl, A. Salvetti, P. Moullier, J. M. Heard, Blood 92, 1512 (1998); K. G. Rendahl et al., Nature Biotechnol. 16, 757 (1998); V. M. Rivera et al., Proc. Natl. Acad. Sci. U.S.A. 96, 8657 (1999); X. Ye et al., Science 283, 88 (1999).
12. D. Bohl, A. Salvetti, P. Moullier, J. M. Heard, Blood 92, 1512 (1998); K. G. Rendahl et al., Nature Biotechnol. 16, 757 (1998); V. M. Rivera et al., Proc. Natl. Acad. Sci. U.S.A. 96, 8657 (1999); X. Ye et al., Science 283, 88 (1999).
13. D. Bohl, A. Salvetti, P. Moullier, J. M. Heard, Blood 92, 1512 (1998); K. G. Rendahl et al., Nature Biotechnol. 16, 757 (1998); V. M. Rivera et al., Proc. Natl. Acad. Sci. U.S.A. 96, 8657 (1999); X. Ye et al., Science 283, 88 (1999).
14. D. Bohl, A. Salvetti, P. Moullier, J. M. Heard, Blood 92, 1512 (1998); K. G. Rendahl et al., Nature Biotechnol. 16, 757 (1998); V. M. Rivera et al., Proc. Natl. Acad. Sci. U.S.A. 96, 8657 (1999); X. Ye et al., Science 283, 88 (1999).
15. K. S. Polonsky, B. D. Given, E. Van Cauter, J. Clin. Invest. 81, 442 (1988).
16. J. B. Denault and R. Leduc, FEBS Lett. 379, 113 (1996).
17. T. Clackson et al., unpublished data.
18. T. Clackson et al., Proc. Natl. Acad. Sci. U.S.A. 95, 10437 (1998).
19. D. J. Groskreutz, M. X. Sliwkowski, C. M. Gorman, J. Biol. Chem. 269, 6241 (1994).
20. V. M. Rivera, X. Wang, N. L. Courage, unpublished data.
21. M regulatory domain could be prevented: for example, by incorporating an additional domain [F. Q. Li, A. Coonrod, M. Horwitz, J. Cell Biol. 135, 1043 (1996)] to target it to the lysosome after furin cleavage.
22. L. Orci, Diabetes 31, 538 (1982).
23. AP22542 induces secretion in vitro with similar potency to AP21998.
24. M-ln-m3) that produces insulin that also contains a naturally occurring mutation, histidine B10 to aspartic acid, which increases its potency by decreasing its rate of dissociation from the insulin receptor [K. Drejer, Diabetes Metab. Rev. 8, 259 (1992)].
25. AP22542 has an apparent oral bioavailability of ∼20% [S. Wardwell and F. Cerasoli Jr., unpublished data].
26. D. M. Spencer, Trends Genet. 12, 181 (1996).
27. D. A. Holt et al., unpublished data.
28. Aggregate-containing cells grow indefinitely (> 180 doublings) at the same rate as control cells, implying that trafficking of a wide spectrum of critical proteins (including growth factor receptors and adhesion proteins) is functionally unaffected (9). Also, there was no reduction in the amount of protein stored over a 6-month period, indicating that retention of proteins in the ER is a stable phenotype. We also do not detect activation of the ER stress-sensing kinase PERK [H. P. Harding, Y. Zhang, D. Ron, Nature 397, 271 (1999); A. Volchuk, H. P. Harding, D. Ron, unpublished data].
29. Aggregate-containing cells grow indefinitely (> 180 doublings) at the same rate as control cells, implying that trafficking of a wide spectrum of critical proteins (including growth factor receptors and adhesion proteins) is functionally unaffected (9). Also, there was no reduction in the amount of protein stored over a 6-month period, indicating that retention of proteins in the ER is a stable phenotype. We also do not detect activation of the ER stress-sensing kinase PERK [H. P. Harding, Y. Zhang, D. Ron, Nature 397, 271 (1999); A. Volchuk, H. P. Harding, D. Ron, unpublished data].
30. H. Ronne et al., J. Cell Biol. 96, 907 (1983); C. Hammond and A. Helenius, Curr. Opin. Cell Biol. 7, 523 (1995).
31. H. Ronne et al., J. Cell Biol. 96, 907 (1983); C. Hammond and A. Helenius, Curr. Opin. Cell Biol. 7, 523 (1995).
32. R. M. Attar and M. Z. Gilman, Mol. Cell. Biol. 12, 2432 (1992).
33. J. A. Martial, R. A. Hallewell, J. D. Baxter, H. M. Goodman, Science 205, 602 (1979).
34. G. I. Bell et al., Nature 282, 525 (1979).
35. T. T. Yang, L. Cheng, S. R. Kain, Nucleic Acids Res. 24, 4592 (1996).
36. A. Volchuk et al., J. Biol. Chem. 270, 8233 (1995). Primary antibodies used were guinea pig anti-porcine insulin (1:1000 dilution; P. H. Wright, Indiana University, Indianapolis, IN); mouse anti-Grp78 (1:200; StressGen Biotechnologies); mouse anti-GM130 (1:1000; Transduction Laboratories); and mouse anti-COP I coatomer [D. J. Palmer, J. B. Helms, C. J. Beckers, L. Orci, J. E. Rothman, J. Biol. Chem. 268, 12083 (1993)]. Secondary antibodies (1:500) used were fluorescein isothiocyanate-conjugated donkey anti-guinea pig immunoglobulin G (IgG) and Cy5-conjugated donkey anti-mouse IgG (Jackson ImmunoResearch).
37. A. Volchuk et al., J. Biol. Chem. 270, 8233 (1995). Primary antibodies used were guinea pig anti-porcine insulin (1:1000 dilution; P. H. Wright, Indiana University, Indianapolis, IN); mouse anti-Grp78 (1:200; StressGen Biotechnologies); mouse anti-GM130 (1:1000; Transduction Laboratories); and mouse anti-COP I coatomer [D. J. Palmer, J. B. Helms, C. J. Beckers, L. Orci, J. E. Rothman, J. Biol. Chem. 268, 12083 (1993)]. Secondary antibodies (1:500) used were fluorescein isothiocyanate-conjugated donkey anti-guinea pig immunoglobulin G (IgG) and Cy5-conjugated donkey anti-mouse IgG (Jackson ImmunoResearch).
38. Cells were fixed in 2% glutaraldehyde for 30 min at room temperature, embedded in Epon, and stained with uranyl acetate and lead citrate. Cryosections were prepared and immunostained by the protein A-gold technique [J. Roth, M. Bendayan, L. Orci, J. Histochem. Cytochem. 26, 1074 (1978); K. T. Tokuyasu, J. Microsc. 143, 139 (1986)]. Antibodies used were rabbit anti-human growth hormone (1:100) and guinea pig anti-porcine insulin (1:500).
39. Cells were fixed in 2% glutaraldehyde for 30 min at room temperature, embedded in Epon, and stained with uranyl acetate and lead citrate. Cryosections were prepared and immunostained by the protein A-gold technique [J. Roth, M. Bendayan, L. Orci, J. Histochem. Cytochem. 26, 1074 (1978); K. T. Tokuyasu, J. Microsc. 143, 139 (1986)]. Antibodies used were rabbit anti-human growth hormone (1:100) and guinea pig anti-porcine insulin (1:500).
40. Supported by grants from the Swiss National Science Foundation (L.O.) and a postdoctoral fellowship from the Medical Research Council of Canada (A.V.).